Found: 59
Select item for more details and to access through your institution.
A controlled trial of the tolerance of amphotericin B infused in dextrose or in Intralipid in patients with haematological malignancies.
- Published in:
- 1994
- By:
- Publication type:
- journal article
Efficacy and tolerance of an amphotericin B lipid (Intralipid) emulsion in the treatment of candidaemia in neutropenic patients.
- Published in:
- 1993
- By:
- Publication type:
- journal article
Adrenal lymphoma: presentation, management and prognosis.
- Published in:
- QJM: An International Journal of Medicine, 2017, v. 110, n. 2, p. 103, doi. 10.1093/qjmed/hcw174
- By:
- Publication type:
- Article
Dobutamine Stress Echocardiography Identifies Anthracycline Cardiotoxicity.
- Published in:
- European Journal of Echocardiography, 2000, v. 1, n. 3, p. 180, doi. 10.1053/euje.2000.0037
- By:
- Publication type:
- Article
Phase 1b study of lenalidomide in combination with rituximab-CHOP (R2-CHOP) in patients with B-cell lymphoma.
- Published in:
- Leukemia (08876924), 2013, v. 27, n. 1, p. 252, doi. 10.1038/leu.2012.172
- By:
- Publication type:
- Article
High Concentrations of Intrathecal Interleukin-6 in Human Bacterial and Nonbacterial Meningitis.
- Published in:
- Journal of Infectious Diseases, 1992, v. 166, n. 2, p. 428, doi. 10.1093/infdis/166.2.428
- By:
- Publication type:
- Article
Tandem versus single haematopoietic stem cell transplant and BV maintenance in relapsed/refractory Hodgkin lymphoma: A matched cohort analysis from the LYSA.
- Published in:
- British Journal of Haematology, 2023, v. 202, n. 2, p. 379, doi. 10.1111/bjh.18859
- By:
- Publication type:
- Article
Early clearance of peripheral blasts measured by flow cytometry during the first week of AML induction therapy as a new independent prognostic factor: a GOELAMS study.
- Published in:
- Leukemia (08876924), 2009, v. 23, n. 2, p. 350, doi. 10.1038/leu.2008.296
- By:
- Publication type:
- Article
Fc?RIIB expression in diffuse large B-cell lymphomas does not alter the response to CHOP+rituximab (R-CHOP).
- Published in:
- 2004
- By:
- Publication type:
- Letter
Immunological classification of acute myeloblastic leukemias: relevance to patient outcome.
- Published in:
- Leukemia (08876924), 2003, v. 17, n. 3, p. 515, doi. 10.1038/sj.leu.2402821
- By:
- Publication type:
- Article
Minimally differentiated acute myeloid leukemia (AML-MO) with lymphoid presentation at relapse: a case report.
- Published in:
- 2001
- By:
- Publication type:
- case study
Exposure to hydroxyurea during pregnancy: a case series.
- Published in:
- 2001
- By:
- Publication type:
- letter
Phase I study of cinchonine, a multidrug resistance reversing agent, combined with the CHVP regimen in relapsed and refractory lymphoproliferative syndromes.
- Published in:
- 2000
- By:
- Publication type:
- journal article
Immunophenotypic patterns and cytogenetic anomalies in acute non-lymphoblastic leukemia subtypes: a prospective study of 432 patients.
- Published in:
- 1998
- By:
- Publication type:
- journal article
Polyvisceral arteritis in chronic graft-versus-host disease: antiphospholipid-negative thrombotic syndrome mimicking polyarteritis nodosa.
- Published in:
- 2002
- By:
- Publication type:
- Case Study
Early intensive therapy with autologous stem cell transplantation in advanced Hodgkin's disease: retrospective analysis of 158 cases from the French registry.
- Published in:
- Bone Marrow Transplantation, 1998, v. 21, n. 8, p. 787, doi. 10.1038/sj.bmt.1701174
- By:
- Publication type:
- Article
Peripheral blood stem cell transplantation in a multiple myeloma patient with end-stage renal failure.
- Published in:
- Bone Marrow Transplantation, 1997, v. 20, n. 1, p. 63, doi. 10.1038/sj.bmt.1700848
- By:
- Publication type:
- Article
AXICABTAGENE CILOLEUCEL AS SECOND‐LINE THERAPY FOR LARGE B‐CELL LYMPHOMA IN TRANSPLANT‐INELIGIBLE PATIENTS: FINAL ANALYSIS OF ALYCANTE, A PHASE 2 LYSA STUDY.
- Published in:
- Hematological Oncology, 2023, v. 41, p. 147, doi. 10.1002/hon.3163_97
- By:
- Publication type:
- Article
CLONAL ARCHITECTURE OF RELAPSED OR REFRACTORY FOLLICULAR HELPER T‐CELL LYMPHOMA: AN ANCILLARY STUDY OF THE ORACLE TRIAL, A LYSA STUDY.
- Published in:
- Hematological Oncology, 2023, v. 41, p. 108, doi. 10.1002/hon.3163_69
- By:
- Publication type:
- Article
RITUXIMAB AND IBRUTINIB COMBINATION IS SAFE AND EFFECTIVE IN UNTREATED SPLENIC AND NODAL MARGINAL ZONE LYMPHOMAS: PLANNED SUBSET ANALYSIS OF THE IELSG47/MALIBU PHASE II STUDY.
- Published in:
- Hematological Oncology, 2023, v. 41, p. 104, doi. 10.1002/hon.3163_65
- By:
- Publication type:
- Article
RISK STRATIFICATION OF DLBCL WITH MVED2 SCORE USING INTEGRATIVE HOST ADIPOSE DENSITY AND METABOLIC TUMOR CHARACTERISTICS COMPARED TO OTHER INDEXES.
- Published in:
- Hematological Oncology, 2023, v. 41, p. 91, doi. 10.1002/hon.3163_55
- By:
- Publication type:
- Article
Transfusion needs after CD19 CAR T‐cells for large B‐cell lymphoma: predictive factors and impact on outcome. A DESCAR‐T study.
- Published in:
- Hematological Oncology, 2023, v. 41, p. 534, doi. 10.1002/hon.3164_397
- By:
- Publication type:
- Article
Long term follow‐up of untreated/relapsing MCL patients with the Ibrutinib, obinutuzumab, and venetoclax combination.
- Published in:
- Hematological Oncology, 2023, v. 41, p. 478, doi. 10.1002/hon.3164_352
- By:
- Publication type:
- Article
Prognostic Value of Lymphopenia and Total Metabolic Tumor Volume in Diffuse Large Cell Lymphoma of B Phenotype in the RT3 and REMARC trials—A LYSA retrospective analysis.
- Published in:
- Hematological Oncology, 2023, v. 41, p. 346, doi. 10.1002/hon.3164_248
- By:
- Publication type:
- Article
Cell‐free DNA sequencing allows the identification of the mutational profile of TFH lymphomas and has a predictive value: a LYSA study.
- Published in:
- Hematological Oncology, 2023, v. 41, p. 338, doi. 10.1002/hon.3164_241
- By:
- Publication type:
- Article
Distinct molecular determinants of treatment‐failure in elderly Hodgkin lymphoma identified by cell‐free DNA profiling: A LYSA Study.
- Published in:
- Hematological Oncology, 2023, v. 41, p. 321, doi. 10.1002/hon.3164_228
- By:
- Publication type:
- Article
VERY LONG‐TERM FOLLOW‐UP OF RITUXIMAB MAINTENANCE IN YOUNG PATIENTS WITH MANTLE CELL LYMPHOMA INCLUDED IN THE LYMA TRIAL, A LYSA STUDY.
- Published in:
- Hematological Oncology, 2023, v. 41, p. 151, doi. 10.1002/hon.3163_100
- By:
- Publication type:
- Article
LONG‐TERM OUTCOMES OF ELDERLY PATIENTS TREATED WITH FRONTLINE R‐CHOP: UPDATE OF THE LNH03‐6B TRIAL.
- Published in:
- Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.96_2880
- By:
- Publication type:
- Article
SELINEXOR IN COMBINATION WITH R‐GDP FOR PATIENTS WITH RELAPSED/REFRACTORY B‐CELL LYMPHOMA: PRELIMINARY RESULTS OF THE SELINDA PHASE IB LYSA STUDY (EUDRACT NUMBER: 2015‐005612‐15)
- Published in:
- Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.88_2880
- By:
- Publication type:
- Article
SELINEXOR IN COMBINATION WITH R‐GDP FOR PATIENTS WITH RELAPSED/REFRACTORY B‐CELL LYMPHOMA: PRELIMINARY RESULTS OF THE SELINDA PHASE IB LYSA STUDY (EUDRACT NUMBER: 2015‐005612‐15)
- Published in:
- Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.87_2880
- By:
- Publication type:
- Article
FIRST RESULTS OF DLBCL PATIENTS TREATED WITH CAR‐T CELLS AND ENROLLED IN DESCAR‐T REGISTRY, A FRENCH REAL‐LIFE DATABASE FOR CAR‐T CELLS IN HEMATOLOGIC MALIGNANCIES.
- Published in:
- Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.84_2879
- By:
- Publication type:
- Article
HIGH ADIPOSE TISSUE DENSITY IS A NEGATIVE PROGNOSTIC FACTOR IN DLBCL PATIENTS TREATED BY R‐CHOP, INDEPENDENT FROM TMTV AND PS –FROM THE REMARC STUDY.
- Published in:
- Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.78_2880
- By:
- Publication type:
- Article
ACALABRUTINIB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: FINAL RESULTS FROM A PHASE 2 STUDY.
- Published in:
- Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.58_2880
- By:
- Publication type:
- Article
PHASED VARIANTS IMPROVE DLBCL MINIMAL RESIDUAL DISEASE DETECTION AT THE END OF THERAPY.
- Published in:
- Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.25_2879
- By:
- Publication type:
- Article
ATEZOLIZUMAB + OBINUTUZUMAB + VENETOCLAX IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: PRIMARY ANALYSIS OF A PHASE 2 TRIAL FROM LYSA.
- Published in:
- Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.22_2880
- By:
- Publication type:
- Article
DEFINING ULTRA‐HIGH‐RISK DLBCL PATIENTS PRIOR TO INITIAL TREATMENT BASED ON AN INTEGRATIVE HOST AND DISEASE PROGNOSTIC SCORE (FROM REMARC STUDY)
- Published in:
- Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.17_2879
- By:
- Publication type:
- Article
PROSPECTIVE EVALUATION OF LYMPHOMA RESPONSE TO IMMUNOMODULATORY THERAPY CRITERIA (LYRIC) IN GATA TRIAL FROM THE LYSA GROUP.
- Published in:
- Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.157_2880
- By:
- Publication type:
- Article
BRENTUXIMAB VEDOTIN AS CONSOLIDATION TREATMENT IN PATIENTS WITH STAGE I/II CLASSICAL HODGKIN'S LYMPHOMA AND A POSITIVE FDG‐PET AFTER 2 CYCLES OF ABVD: A LYSA PHASE 2 STUDY.
- Published in:
- Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.111_2880
- By:
- Publication type:
- Article
BONE MARROW INVOLVEMENT, BUT NO BLOOD INVOLVEMENT, IMPAIRS SURVIVAL IN ANGIOIMMUNOBLASTIC T CELL LYMPHOMA: AN ANCILLARY STUDY OF THE REVAIL TRIAL.
- Published in:
- Hematological Oncology, 2019, v. 37, p. 278, doi. 10.1002/hon.89_2630
- By:
- Publication type:
- Article
RITUXIMAB PLUS LENALIDOMIDE IS AS EFFECTIVE AS IMMUNOCHEMOTHERAPY IN THE ERADICATION OF MOLECULAR DISEASE IN UNTREATED FOLLICULAR LYMPHOMA: RELEVANCE LYSA ANCILLARY STUDY.
- Published in:
- Hematological Oncology, 2019, v. 37, p. 117, doi. 10.1002/hon.77_2629
- By:
- Publication type:
- Article
EFFICACY AND SAFETY OF OBINUTUZUMAB + LENALIDOMIDE + ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: PRIMARY ANALYSIS OF A PHASE 1B/2 TRIAL.
- Published in:
- Hematological Oncology, 2019, v. 37, p. 113, doi. 10.1002/hon.74_2629
- By:
- Publication type:
- Article
EFFICACY AND SAFETY OF PROLONGED MAINTENANCE WITH SUBCUTANEOUS RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY INDOLENT NHL: RESULTS OF THE PHASE III MABCUTE STUDY.
- Published in:
- Hematological Oncology, 2019, v. 37, p. 229, doi. 10.1002/hon.43_2630
- By:
- Publication type:
- Article
A PHASE 2B STUDY OF SELINEXOR IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL).
- Published in:
- Hematological Oncology, 2019, v. 37, p. 62, doi. 10.1002/hon.31_2629
- By:
- Publication type:
- Article
HIGH TOTAL METABOLIC TUMOR VOLUME AT BASELINE ALLOWS TO DISCRIMINATE FOR SURVIVAL PATIENTS IN RESPONSE AFTER R‐CHOP: AN ANCILLARY ANALYSIS OF THE REMARC STUDY.
- Published in:
- Hematological Oncology, 2019, v. 37, p. 49, doi. 10.1002/hon.19_2629
- By:
- Publication type:
- Article
POOLED RESULTS OF THREE ANNUAL COHORTS FROM AN OBSERVATIONAL PROSPECTIVE STUDY DESCRIBING BRENTUXIMAB VEDOTIN USE IN ROUTINE PRACTICE IN FRANCE FOR HODGKIN LYMPHOMA: INTERIM ANALYSIS.
- Published in:
- Hematological Oncology, 2019, v. 37, p. 492, doi. 10.1002/hon.170_2631
- By:
- Publication type:
- Article
REFINEMENT OF MUM1 EXPRESSION THRESHOLD FOR DOUBLE POSITIVE CD10+ MUM1+ DIFFUSE LARGE B CELL LYMPHOMA ALLOWS A BETTER CELL OF ORIGIN CLASSIFICATION FOR GCB SUBTYPE.
- Published in:
- Hematological Oncology, 2019, v. 37, p. 197, doi. 10.1002/hon.11_2630
- By:
- Publication type:
- Article
BONE MARROW INVOLVEMENT, BUT NO BLOOD INVOLVEMENT, IMPAIRS SURVIVAL IN ANGIOIMMUNOBLASTIC T CELL LYMPHOMA: AN ANCILLARY STUDY OF THE REVAIL TRIAL.
- Published in:
- Hematological Oncology, 2019, v. 37, p. 278, doi. 10.1002/hon.89_2630
- By:
- Publication type:
- Article
RITUXIMAB PLUS LENALIDOMIDE IS AS EFFECTIVE AS IMMUNOCHEMOTHERAPY IN THE ERADICATION OF MOLECULAR DISEASE IN UNTREATED FOLLICULAR LYMPHOMA: RELEVANCE LYSA ANCILLARY STUDY.
- Published in:
- Hematological Oncology, 2019, v. 37, p. 117, doi. 10.1002/hon.77_2629
- By:
- Publication type:
- Article
EFFICACY AND SAFETY OF OBINUTUZUMAB + LENALIDOMIDE + ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: PRIMARY ANALYSIS OF A PHASE 1B/2 TRIAL.
- Published in:
- Hematological Oncology, 2019, v. 37, p. 113, doi. 10.1002/hon.74_2629
- By:
- Publication type:
- Article
EFFICACY AND SAFETY OF PROLONGED MAINTENANCE WITH SUBCUTANEOUS RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY INDOLENT NHL: RESULTS OF THE PHASE III MABCUTE STUDY.
- Published in:
- Hematological Oncology, 2019, v. 37, p. 229, doi. 10.1002/hon.43_2630
- By:
- Publication type:
- Article